Truist Securities Downgrades Axonics to Hold, Lowers Price Target to $71
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Rescott has downgraded Axonics (NASDAQ:AXNX) from Buy to Hold and reduced the price target from $73 to $71.
January 16, 2024 | 8:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Axonics was downgraded by Truist Securities from Buy to Hold with a price target decrease from $73 to $71.
Downgrades by analysts can lead to a negative perception among investors, potentially causing short-term price declines. The reduction in the price target further suggests a tempered outlook for the company's stock performance.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100